Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections.

Rhee KY, Gardiner DF.

Clin Infect Dis. 2004 Sep 1;39(5):755-6. No abstract available.

PMID:
15356797
2.

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.

Pankey GA, Sabath LD.

Clin Infect Dis. 2004 Mar 15;38(6):864-70. Epub 2004 Mar 1. Review.

PMID:
14999632
3.
4.

Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing.

Hecht DW.

Anaerobe. 2006 Jun;12(3):115-21. Epub 2005 Dec 6. Review. No abstract available.

PMID:
16765857
5.

[Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens].

Stefani S, Esposito S.

Infez Med. 2006 Dec;14(4):179-96. Review. Italian.

6.

Pharmacoeconomics of treatment with the newer anti-Gram-positive agents.

Wang L, Barrett JF.

Expert Opin Pharmacother. 2006 May;7(7):885-97. Review.

PMID:
16634711
7.
8.

Tigecycline: clinical evidence and formulary positioning.

Nathwani D.

Int J Antimicrob Agents. 2005 Mar;25(3):185-92. Review.

PMID:
15737510
9.

Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.

Garrison MW, Neumiller JJ, Setter SM.

Clin Ther. 2005 Jan;27(1):12-22. Review.

PMID:
15763603
10.

Daptomycin - a novel antibiotic against Gram-positive pathogens.

LaPlante KL, Rybak MJ.

Expert Opin Pharmacother. 2004 Nov;5(11):2321-31. Review.

PMID:
15500379
11.

[Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].

Jankowski A, Stefanik W.

Wiad Lek. 2006;59(9-10):727-31. Review. Polish.

PMID:
17338140
12.

[Improvement of bactericide activity in hospital treatment of gram positive infections].

Aguilar L, Barberán J, Prieto J, Giménez M.

Rev Esp Quimioter. 2008 Mar;21(1):37-44. Review. Spanish.

13.

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.

Cornaglia G, Rossolini GM.

Clin Microbiol Infect. 2009 Mar;15(3):218-23. doi: 10.1111/j.1469-0691.2009.02740.x. Review.

14.

Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.

Pea F, Viale P.

Expert Rev Anti Infect Ther. 2007 Apr;5(2):255-70. Review.

PMID:
17402840
15.

Dalbavancin: a new option for the treatment of gram-positive infections.

Lin SW, Carver PL, DePestel DD.

Ann Pharmacother. 2006 Mar;40(3):449-60. Epub 2006 Feb 28. Review.

PMID:
16507624
16.

Tigecycline: a novel glycylcycline antibiotic.

Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):9-25. Review.

PMID:
16441206
17.
18.

Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.

Sincak CA, Schmidt JM.

Ann Pharmacother. 2009 Jun;43(6):1107-14. doi: 10.1345/aph.1L167. Epub 2009 May 12. Review.

PMID:
19435963
19.

[Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].

Hernández Martí V, Romá Sánchez E, Salavert Lletí M, Bosó Ribelles V, Poveda Andrés JL.

Rev Esp Quimioter. 2007 Sep;20(3):261-76. Review. Spanish.

20.

Daptomycin.

Enoch DA, Bygott JM, Daly ML, Karas JA.

J Infect. 2007 Sep;55(3):205-13. Epub 2007 Jul 16. Review.

PMID:
17629567

Supplemental Content

Support Center